Efficacy of Vaped Cannabidiol in Cannabis Use Disorder
NCT07933081, Not applicable, Not yet recruiting, University Hospital, Bordeaux
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy of Vaped Cannabidiol in Cannabis Use Disorder | ClinicalTrials.gov |
| NCT number | NCT07933081 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 242 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Bordeaux | ClinicalTrials.gov |
| Conditions | Cannabis Use Disorder | ClinicalTrials.gov |
| Interventions | CBD vape liquid, Placebo Liquid | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Proportion of patients with a reduction of at least 50% in the total reported amount of cannabis consumed - 12 weeks | From baseline to 12 weeks | Proportion of patients for whom the intervention was successful, defined as a reduction of at least 50% in the total reported amount of cannabis consumed (in grams) at the end of the 12-week follow-up period, compared to baseline. | ClinicalTrials.gov |
| Secondary | Proportion of patients with a reduction of at least 50% in the total reported amount of cannabis consumed - 6 months | From baseline to 6 months | Proportion of patients who responded to the intervention, defined as a reduction of at least 50% in the reported amount of cannabis consumed in grams at 6 months compared to baseline | ClinicalTrials.gov |
| Secondary | Total amount of cannabis consumed | At 12 weeks | Total amount of cannabis consumed in grams at the end of the 12-week follow-up period | ClinicalTrials.gov |
| Secondary | Number of days of cannabis abstinence - 12 weeks | From baseline to 12 weeks | Number of days of cannabis abstinence at the end of the 12-week period | ClinicalTrials.gov |
| Secondary | Number of days of cannabis abstinence - 6 months | From baseline to 6 months | Number of days of cannabis abstinence at 6 months | ClinicalTrials.gov |
| Secondary | Self-reported number of joints smoked - 12 weeks | From baseline to 12 weeks | Self-reported number of joints smoked per day at 12 weeks | ClinicalTrials.gov |
| Secondary | Self-reported number of joints smoked - 6 months | From baseline to 6 months | Self-reported number of joints smoked per day at 6 months | ClinicalTrials.gov |
| Secondary | Self-reported budget spent in euros to purchase cannabis - 12 weeks | From baseline to 12 weeks | Self-reported budget spent in euros to purchase cannabis at the end of the 12 weeks | ClinicalTrials.gov |
| Secondary | Self-reported budget spent in euros to purchase cannabis - 6 months | From baseline to 6 months | Self-reported budget spent in euros to purchase cannabis at 6 months | ClinicalTrials.gov |
| Secondary | Self-reported number of cigarettes smoked - 12 weeks | From baseline to 12 weeks | Self-reported number of cigarettes smoked per day at 12 weeks | ClinicalTrials.gov |
| Secondary | Self-reported number of cigarettes smoked - 6 months | From baseline to 6 months | Self-reported number of cigarettes smoked per day at 6 months | ClinicalTrials.gov |
| Secondary | Exhaled carbon monoxide | At 12 weeks | Exhaled carbon monoxide measured in parts per million (ppm) of CO per unit of air using an exhaled carbon monoxide tester at 12 weeks | ClinicalTrials.gov |
| Secondary | Self-reported consumption of psychoactive substances - 12 weeks | At 12 weeks | Self-reported consumption of psychoactive substances in units or grams per week (alcohol, cocaine, ketamine, new synthetic drugs, heroin, other opioids, etc.) at 12 weeks | ClinicalTrials.gov |
| Secondary | Self-reported consumption of psychoactive substances - 6 months | At 6 months | Self-reported consumption of psychoactive substances in units or grams per week (alcohol, cocaine, ketamine, new synthetic drugs, heroin, other opioids, etc.) at 6 months | ClinicalTrials.gov |
| Secondary | Cannabis Withdrawal | At 12 weeks | Cannabis Withdrawal Scale score at 12 weeks It is a 19-item questionnaire assessing cannabis withdrawal symptoms and their impact on daily activities. Each of the 19 items is rated on a scale from 0 to 10. Two separate scores are calculated: Personal experience (withdrawal intensity) (min 0; max 190) and Negative impact on daily activities (min 0 max 190) Higher scores indicate more severe cannabis withdrawal symptoms. Higher negative-impact scores indicate greater interference with daily activities. A decrease in either score indicates improvement. An increase in either score indicates worsening. | ClinicalTrials.gov |
| Secondary | Use of symptomatic treatments | From baseline to 12 weeks | Use of symptomatic treatments for withdrawal symptoms during the 12-week follow-up | ClinicalTrials.gov |
| Secondary | Cannabis cravings at 12 weeks | At 12 weeks | Visual Analog Scale for cannabis cravings at 12 weeks It is used to measure the intensity of an individual's craving or urge to use cannabis. Score range (min: 0 max: 100-mm or min=0 max:10 Interpretation: 0: No craving at all; 100 mm (or 10): Extremely intense craving. A decrease in score indicates reduced cannabis craving (improvement). | ClinicalTrials.gov |
| Secondary | Cannabis cravings at 6 months | At 6 months | Visual Analog Scale for cannabis cravings at 6 months It is used to measure the intensity of an individual's craving or urge to use cannabis. Score range (min: 0 max: 100-mm or min=0 max:10 Interpretation: 0: No craving at all; 100 mm (or 10): Extremely intense craving. A decrease in score indicates reduced cannabis craving (improvement). | ClinicalTrials.gov |
| Secondary | Anxiety and Depression at 12 weeks | At 12 weeks | Hospital Anxiety and Depression scale at 12 weeks Sef-reported questionnaire. It consists of 14 items, divided into two subscales: Anxiety: (min 0 and max 21); Depression (min 0 and max 21)) For each subscale (anxiety and depression): Score: 0-7 (Normal); 8-10 (Borderline / possible symptoms); 11-21 (Abnormal / clinically significant symptoms). Higher scores = worse outcome The anxiety and depression subscales are generally reported and analysed separately. The total score (0-42) can also be used as a measure of overall psychological distress. | ClinicalTrials.gov |
| Secondary | Anxiety and Depression at 6 months | At 6 months | Hospital Anxiety and Depression scale at 6 months Sef-reported questionnaire. It consists of 14 items, divided into two subscales: Anxiety: (min 0 and max 21); Depression (min 0 and max 21)) For each subscale (anxiety and depression): Score: 0-7 (Normal); 8-10 (Borderline / possible symptoms); 11-21 (Abnormal / clinically significant symptoms). Higher scores = worse outcome The anxiety and depression subscales are generally reported and analysed separately. The total score (0-42) can also be used as a measure of overall psychological distress. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)